VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today ...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after ...
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced Monday that it will implement a 1-for-25 reverse stock split of its issued and outstanding common shares, effective at 5:00 p.m. Eastern Time on ...
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) stock is skyrocketing on Wednesday, with a session volume of 2.73 million compared to the average volume of 389.09 thousand, as per data from Benzinga Pro ...
Processa Pharmaceuticals ( (PCSA)) just unveiled an announcement. On December 12, 2025, Processa Pharmaceuticals announced a 1-for-25 reverse stock split of its common stock, effective December 16, ...
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct ...
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results